Skip Ribbon Commands
Skip to main content

​​​​​​

​​

Primary Diagnosis

Heart Failure

Study Purpose

To evaluate the efficacy of sacubitril/valsartan versus enalapril on changes in NT-proBNP and the safety and tolerability of in-patient initiation of sacubitril/valsartan compared to enalapril in patients admitted for heart failure.

Principal Investigator: Steven Kindsvater, MD

Trial Details

Locations: Baylor Scott & White The Heart Hospital – Plano and Baylor Scott & White Medical Center McKinney

Sponsor: Novartis

IRB Number: 017-093

Trial Status: Enrolling

Exclusions: Adults only

Change in Care: Participating will ​change your care

Contact Information:

Alexandria Biberstein, RN
469.814.4732
Alexandria.Biberstein@BSWHealth.org

Julie McCracken
469.814.4717
Julie.McCracken@BSWHealth.org​

Full Protocol Title

A multicenter, randomized, double-blind, double-dummy, parallel group, active-controlled 8-week study to evaluate the effect of sacubitril/valsartan (LCZ696) versus enalapril on changes in NT-proBNP and safety and tolerability of in-hospital initiation of sacubitril/valsartan compared to enalapril in HFrEF patients who have been stabilized following hospitalization for acute decompensated heart failure (ADHF).

Get Detailed Infor​m​ation O​n Clinicaltrials.gov »​​​​​​​​​​​​​​​​​​​​​

​​

​​

​​​​​​​​​​BAYLOR SCOTT & WHITE RESEARCH ​INSTITUTE​​